Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
项目1:通过表观遗传重编程克服胰腺癌的治疗耐药性
基本信息
- 批准号:10629063
- 负责人:
- 金额:$ 50.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-06 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAntigen PresentationAntineoplastic AgentsAutophagocytosisBiopsyCancer Cell GrowthCell CommunicationCell CompartmentationCell DeathCell ProliferationCellsChemoresistanceChromatinClinicalClinical TrialsCollaborationsComplexCytotoxic T-LymphocytesDNA DamageDNA RepairDataDiseaseDisease ProgressionDoseDown-RegulationDrug Delivery SystemsEpigenetic ProcessExhibitsExtracellular MatrixFibroblastsGene ExpressionGene Expression ProfileGenesGeneticGenetic TranscriptionHDAC1 geneHeterogeneityHistone AcetylationHistone DeacetylaseHistone Deacetylase InhibitorHistonesHumanI-antigenImmuneImmunologicsImmunotherapyIn VitroIncidenceInduction of ApoptosisInflammatoryIntercellular FluidLIF geneLaboratory FindingMalignant NeoplasmsMalignant neoplasm of pancreasMapsMediatingMediatorMetabolicMolecularMusMutationOrganoidsOutcomePancreatic Ductal AdenocarcinomaPathway interactionsPatient-Focused OutcomesPatientsPhenotypePopulationProductionPrognosisRefractoryRegulationResistanceRoleSignal TransductionStromal CellsSystemT-LymphocyteTestingTherapeuticTissuesToxic effectTreatment EfficacyTumor BurdenTumor ImmunityTumor PromotionWorkanti-PD-1anti-PD1 therapyanti-tumor immune responsecell growthcell typecheckpoint inhibitioncytokinedigitaldrug sensitivityefficacy testingepigenomeepigenomicsexperimental studygenetic approachimmunogenicimmunoregulationimprovedin vivoinhibition of autophagyinhibitorinsightmouse modelnano-stringnanoparticlenanoparticle deliveryneoplastic cellnovelnovel therapeuticspancreatic cancer cellspancreatic ductal adenocarcinoma modelpharmacologicpreventprogramsreconstitutionresponsesynergismtargeted treatmenttherapy resistanttranscriptional reprogrammingtreatment responsetreatment strategytumortumor growthtumor microenvironmenttumorigenic
项目摘要
PROJECT SUMMARY – Project 1: Epigenetics
Pancreatic ductal adenocarcinoma (PDA) is a devastating disease with a disturbing rise in incidence. The poor
prognosis of PDA is attributed, in large part, to inherent resistance to conventional chemo- and immuno-
therapies. Multifactorial contributions from tumor intrinsic and extrinsic epigenomic programs, an elaborate
network of cell-cell communications within the tumor microenvironment (TME), and complex metabolic
adaptations compound to make PDA refractory to the current arsenal of therapies. Proposed experiments use
both pharmacological and genetic targeting of Class I histone deacetylases (HDACs) to determine the
contributions of epigenetically encoded programs to therapeutic resistance. Aim 1 expands on the lab’s finding
that HDAC inhibition (HDACi) leads to a downregulation of DNA damage response pathway genes. The ability
of HDACi to sensitize both organoid and mouse models of PDA to DNA damaging agents is tested by employing
a nanoparticle delivery system that circumvents systemic HDAC inhibitor toxicities in vivo. Given preliminary
evidence that HDACi upregulates autophagy, a known mediator of therapeutic resistance, the ability of
autophagy inhibition to potentiate responses to HDACi (and combinations with DNA damaging agents) is tested
in collaboration with Project 3. Moreover, interrogation of a human organoid bank will delineate how different
mutational profiles impact sensitivities to HDACi and DNA damage. Aim 2 delineates the contribution of HDAC-
regulated epigenetic programs in cancer-associated fibroblasts (CAFs), a heterogenous cell type within the TME,
to PDA outcomes. Preliminary data identifies HDAC1 as the primary HDAC underlying CAF responses to
pharmacological HDACi in vitro. Here, a genetic approach is taken to determine how HDAC1 loss in fibroblasts
impacts CAF functional heterogeneity, tumor growth, and chemoresistance in vivo. Collaborative efforts with
Project 2 elucidate how HDACi influences stromal support of tumor growth and chemoresistance through
alterations in CAF-derived soluble factors, including LIF. In addition, the molecular mechanisms by which HDACi
rewires the epigenome in specific CAF subpopulations is delineated. Lastly, Aim 3 builds on preliminary findings
that HDACi sensitizes PDA mouse models to immune checkpoint inhibition (ICI). In collaboration with Project 3,
the ability of HDACi and autophagy blockade to synergize in promoting ICI responses through convergent
regulation of MHC-I is tested. The possibility of enhancing anti-tumor immunity by inducing immunological cell
death through the combination of HDACi and DNA damaging agents is also explored. In collaboration with
Project 2, how STAT signaling in inflammatory CAF populations influences anti-tumor immunity elicited by
HDACi and ICI is defined. Finally, to determine how HDACi reprograms immunomodulatory features in human
PDA, biopsies from a completed clinical trial combining HDACi and anti-PD-1 ICI are analyzed via digital spatial
profiling. Together, these studies provide critical insight into the epigenetic mechanisms underlying therapeutic
resistance in PDA and explore novel treatment strategies with the potential to improve patient outcomes.
项目摘要 – 项目 1:表观遗传学
胰腺导管腺癌(PDA)是一种毁灭性的疾病,其发病率的上升令人不安。穷人
PDA 的预后在很大程度上归因于对传统化疗和免疫治疗的固有抵抗
疗法。肿瘤内在和外在表观基因组程序的多因素贡献,一个精心设计的
肿瘤微环境(TME)内的细胞间通讯网络和复杂的代谢
适应性复合使 PDA 对当前的治疗方法无效。提议的实验用途
I 类组蛋白脱乙酰酶 (HDAC) 的药理学和遗传靶向,以确定
表观遗传编码程序对治疗耐药性的贡献。目标 1 扩展了实验室的发现
HDAC 抑制 (HDACi) 会导致 DNA 损伤反应途径基因的下调。能力
HDACi 使 PDA 的类器官和小鼠模型对 DNA 损伤剂敏感的实验通过使用
一种纳米颗粒递送系统,可规避体内 HDAC 抑制剂的全身毒性。初步给出
有证据表明 HDACi 上调自噬,这是一种已知的治疗耐药性介质,
测试了自噬抑制以增强对 HDACi(以及与 DNA 损伤剂的组合)的反应
与项目 3 合作。此外,对人类类器官库的询问将描绘出有何不同
突变谱影响对 HDACi 和 DNA 损伤的敏感性。目标 2 描述了 HDAC 的贡献-
癌症相关成纤维细胞(CAF)(TME 中的一种异质细胞类型)中受调控的表观遗传程序,
PDA 结果。初步数据表明 HDAC1 是 CAF 响应的主要 HDAC
体外药理学 HDACi。在这里,采用遗传方法来确定成纤维细胞中 HDAC1 的丢失是如何发生的
影响 CAF 功能异质性、肿瘤生长和体内化疗耐药性。与以下机构的共同努力
项目 2 阐明 HDACi 如何通过以下方式影响肿瘤生长的基质支持和化疗耐药性:
CAF 衍生的可溶性因子(包括 LIF)的改变。此外,HDACi 的分子机制
描述了特定 CAF 亚群中表观基因组的重新连接。最后,目标 3 基于初步发现
HDACi 使 PDA 小鼠模型对免疫检查点抑制 (ICI) 敏感。与项目 3 合作,
HDACi 和自噬阻断通过收敛协同促进 ICI 反应的能力
测试了 MHC-I 的调节。通过诱导免疫细胞增强抗肿瘤免疫力的可能性
还探讨了 HDACi 和 DNA 损伤剂组合导致的死亡。与合作
项目 2,炎症性 CAF 群体中的 STAT 信号如何影响由
HDACi 和 ICI 已定义。最后,确定 HDACi 如何重新编程人类的免疫调节特征
PDA,通过数字空间分析结合 HDACi 和抗 PD-1 ICI 的已完成临床试验的活检样本
分析。总之,这些研究为治疗背后的表观遗传机制提供了重要的见解。
PDA 耐药性并探索有可能改善患者预后的新治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RONALD M EVANS其他文献
RONALD M EVANS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RONALD M EVANS', 18)}}的其他基金
Tissue-specific roles of FXR in CVD and NASH
FXR 在 CVD 和 NASH 中的组织特异性作用
- 批准号:
10461065 - 财政年份:2020
- 资助金额:
$ 50.89万 - 项目类别:
Tissue-specific roles of FXR in CVD and NASH
FXR 在 CVD 和 NASH 中的组织特异性作用
- 批准号:
10262919 - 财政年份:2020
- 资助金额:
$ 50.89万 - 项目类别:
Tissue-specific roles of FXR in CVD and NASH
FXR 在 CVD 和 NASH 中的组织特异性作用
- 批准号:
10683976 - 财政年份:2020
- 资助金额:
$ 50.89万 - 项目类别:
Engineering human islet-like organoids for transplantation
工程化人类胰岛样器官用于移植
- 批准号:
10161781 - 财政年份:2018
- 资助金额:
$ 50.89万 - 项目类别:
Engineering human islet-like organoids for transplantation
工程化人类胰岛样器官用于移植
- 批准号:
9788431 - 财政年份:2018
- 资助金额:
$ 50.89万 - 项目类别:
BD2K: INTEROPERABILITY OF NURSA WITH PHARMGKB AND DKNET
BD2K:NURSA 与 PARMGKB 和 DKNET 的互操作性
- 批准号:
9057203 - 财政年份:2012
- 资助金额:
$ 50.89万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 50.89万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 50.89万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 50.89万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 50.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 50.89万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 50.89万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 50.89万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 50.89万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 50.89万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 50.89万 - 项目类别:














{{item.name}}会员




